Management

Dr Ian Pike – Chief Business Officer

Ian Pike has over 15 years experience working in the diagnostics and biotechnology sectors. Having gained a PhD in Medical Microbiology, he joined Wellcome Diagnostics as a research group leader and spent 8 years working on new diagnostic assays, particularly for hepatitis. In December 1999, he joined the Technology Transfer Office of the UK Medical Research Council with responsibility for patents and commercialisation of a wide portfolio of technologies related to the biomedical sector. Most recently, Ian worked for Cancer Research Ventures managing intellectual property and performing business development activities in Europe and the USA.

Dr. Rainer. Voegeli – Commercial Director

Dr. Rainer Voegeli joined Proteome Sciences in September 2007 after being Head of Business Development at BioVisioN AG (later Digilab BioVisioN GmbH) where he concluded deals with many major pharmaceutical companies. Before moving into Biotechnology, he worked for ASTA Medica AG in research and business development positions in Germany and the USA. Rainer Voegeli qualified with a PhD in biochemistry at the University of Giessen, Germany and has developed considerable proteomics expertise in peptides and proteins.

Malcolm Ward – Head, London Research Facility

Malcolm Ward joined Proteome Sciences plc in May 2001 having previously worked for GlaxoWellcome for 12 years, primarily undertaking analyses of proteins using mass spectrometry. He was a driving force in the establishment of the new leading edge protein separation and mass spectrometry facility located within the Institute of Psychiatry, King’s College London. His research team is involved in a number of proteomics projects focused towards the discovery and development of new diagnostic tests and therapeutic agents to address several key human diseases. His academic qualifications include a Master of Science (MSc) in Molecular Biology from the University of Hertfordshire in 1996 and a Graduateship from the Royal Society of Chemistry (GRSC) in 1992.

Dr Josef Schwarz – Head of Science, Frankfurt Research Facility

Joseph Schwarz joined the Group in summer 2002 when Xzillion, the former proteomics division of Aventis Research and Technologies, was acquired by Proteome Sciences plc. He worked for Aventis/Hoechst Research and Technologies for 6 years, initially as head of mass spectrometry and later as research collaboration project leader. He was instrumental in the establishment of the integrated high throughput 2DE/mass spectrometry proteomics platform at the Frankfurt research facility. Josef Schwarz holds a PhD in organic chemistry/mass spectrometry from the Technical University of Berlin, Germany and a MBA from the University of Durham, UK. He is an author of a number of publications and co-inventor of patents.

Uwe Jöckel – Head of Administration, Frankfurt Research Facility

Uwe Jöckel joined the Group in November 2006. He worked for over 7 years in the German telecommunications market with a focus on Finance, Controlling and Business Planning. In addition, he worked for 9 years in the banking sector as an internal auditor and administration manager. Uwe Jockel has a degree in Business Administration from the University for Applied Sciences in Frankfurt am Main and holds a degree in Master of Arts.